182 related articles for article (PubMed ID: 35217913)
1. Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data.
de Bardeci M; Greil W; Stassen H; Willms J; Köberle U; Bridler R; Hasler G; Kasper S; Rüther E; Bleich S; Toto S; Grohmann R; Seifert J
Eur Arch Psychiatry Clin Neurosci; 2023 Feb; 273(1):65-74. PubMed ID: 35217913
[TBL] [Abstract][Full Text] [Related]
2. [Effect of the direct healthcare professional communication on citalopram and escitalopram drug utilization for inpatient treatment of anxiety disorders].
Köberle U; Grohmann R; Belz M; Greil W; Degner D
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Nov; 65(11):1204-1212. PubMed ID: 36169703
[TBL] [Abstract][Full Text] [Related]
3. Implementation of warnings from Dear Doctor Letters (Rote-Hand-Briefe): an analysis of medication data from a large cohort of elderly patients.
Schächtele S; Tümena T; Gaßmann KG; Fromm MF; Maas R
Dtsch Arztebl Int; 2014 Apr; 111(15):255-63. PubMed ID: 24776610
[TBL] [Abstract][Full Text] [Related]
4. Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs.
Chastang A; Renet S; Corny J; Beaussier H; Petre A; Lillo-Lelouet A; Phan Thi TT; Bézie Y
Int J Clin Pharm; 2019 Feb; 41(1):42-48. PubMed ID: 30610545
[TBL] [Abstract][Full Text] [Related]
5. Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting.
Crépeau-Gendron G; Brown HK; Shorey C; Madan R; Szabuniewicz C; Koh S; Veinish S; Mah L
J Affect Disord; 2019 May; 250():341-345. PubMed ID: 30877856
[TBL] [Abstract][Full Text] [Related]
6. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?
Vieweg WV; Hasnain M; Howland RH; Hettema JM; Kogut C; Wood MA; Pandurangi AK
Am J Med; 2012 Sep; 125(9):859-68. PubMed ID: 22748401
[TBL] [Abstract][Full Text] [Related]
7. A comparative study of QT prolongation with serotonin reuptake inhibitors.
Ojero-Senard A; Benevent J; Bondon-Guitton E; Durrieu G; Chebane L; Araujo M; Montastruc F; Montastruc JL
Psychopharmacology (Berl); 2017 Oct; 234(20):3075-3081. PubMed ID: 28770276
[TBL] [Abstract][Full Text] [Related]
8. A question about the potential cardiac toxicity of escitalopram.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2012 Apr; 50(4):17-20. PubMed ID: 22421011
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Ventricular Arrhythmias by QRS/QTc - Ratio in Citalopram or Escitalopram Intoxication.
Dietrichs ES; Smith GL
Front Med (Lausanne); 2022; 9():866454. PubMed ID: 35372426
[TBL] [Abstract][Full Text] [Related]
10. A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers.
Kim A; Lim KS; Lee H; Chung H; Yoon SH; Yu KS; Cho JY; Jang IJ; Chung JY
Int Clin Psychopharmacol; 2016 Jul; 31(4):210-7. PubMed ID: 26950553
[TBL] [Abstract][Full Text] [Related]
11. Low-dose escitalopram for 2 days associated with corrected QT interval prolongation in a middle-aged woman: a case report and literature review.
Tseng PT; Lee Y; Lin YE; Lin PY
Gen Hosp Psychiatry; 2012; 34(2):210.e13-5. PubMed ID: 22133983
[TBL] [Abstract][Full Text] [Related]
12. Citalopram induced torsade de pointes, a rare life threatening side effect.
Kanjanauthai S; Kanluen T; Chareonthaitawee P
Int J Cardiol; 2008 Dec; 131(1):e33-4. PubMed ID: 17919753
[TBL] [Abstract][Full Text] [Related]
13. Development in Prescriptions of Contraindicated and Potentially Harmful QT Interval-Prolonging Drugs in a Large Geriatric Inpatient Cohort From 2011 to 2021.
Then MI; Tümena T; Sledziewska A; Gaßmann KG; Maas R; Fromm MF
Clin Pharmacol Ther; 2023 Feb; 113(2):435-445. PubMed ID: 36471654
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the risk of QT prolongation among SSRIs.
Funk KA; Bostwick JR
Ann Pharmacother; 2013 Oct; 47(10):1330-41. PubMed ID: 24259697
[TBL] [Abstract][Full Text] [Related]
15. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.
Hasnain M; Vieweg WV
CNS Drugs; 2014 Oct; 28(10):887-920. PubMed ID: 25168784
[TBL] [Abstract][Full Text] [Related]
16. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.
Wenzel-Seifert K; Wittmann M; Haen E
Dtsch Arztebl Int; 2011 Oct; 108(41):687-93. PubMed ID: 22114630
[TBL] [Abstract][Full Text] [Related]
17. Citalopram, QTc Prolongation, and Torsades de Pointes.
Tampi RR; Balderas M; Carter KV; Tampi DJ; Moca M; Knudsen A; May J
Psychosomatics; 2015; 56(1):36-43. PubMed ID: 25619672
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
19. Prolonged QTc interval due to escitalopram overdose.
Mohammed R; Norton J; Geraci SA; Newman DB; Koch CA
J Miss State Med Assoc; 2010 Dec; 51(12):350-3. PubMed ID: 21370605
[TBL] [Abstract][Full Text] [Related]
20. A critical evaluation of the cardiac toxicity of citalopram: part 1.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2011 Nov; 49(11):13-6. PubMed ID: 22007855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
